Xenon Pharmaceuticals Inc. (XENE)
Data as of , from SEC Form 4 filings.
See up to 3 months of XENE. The 7-day demo opens the 1M and 3M ranges and puts XENE on your watchlist.
Start 7-day demoLatest XENE insider trades
About Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. is an SEC registrant, filing under CIK 0001582313, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
XENE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 45,000 | $1.68M |
| Open-market sale | 3 | 17,068 | $1.07M |
| Option exercise | 2 | 10,288 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
XENE insider transactions (Form 4)
1833 Form 4 filings on record, the earliest from Nov 22, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gary Patou | Grant or award | Share Option (Right to Buy) | 17,012 | $0.00 | - | |
| Gary Patou | Grant or award | Restricted Share Units | 2,645 | $0.00 | - | |
| Sherry Aulin - Officer | Option exercise | Common Shares | 9,334 | $9.44 | $88K | |
| Sherry Aulin - Officer | Tax withholding / forfeiture | Common Shares | 2,135 | $41.28 | $88K | |
| Sherry Aulin - Officer | Open-market sale | Common Shares | 7,199 | $41.23 | $297K | |
| Sherry Aulin - Officer | Option exercise | Common Shares | 16,000 | $11.58 | $185K | |
| Sherry Aulin - Officer | Tax withholding / forfeiture | Common Shares | 4,490 | $41.28 | $185K | |
| Sherry Aulin - Officer | Open-market sale | Common Shares | 11,510 | $41.19 | $474K | |
| Sherry Aulin - Officer | Option exercise | Stock Option (Right to Buy) | 9,334 | $0.00 | - | |
| Sherry Aulin - Officer | Option exercise | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| Gary Patou | Option exercise | Common Shares | 3,500 | $7.38 | $26K | |
| Gary Patou | Tax withholding / forfeiture | Common Shares | 649 | $39.80 | $26K | |
| Gary Patou | Open-market sale | Common Shares | 2,851 | $41.11 | $117K | |
| Gary Patou | Option exercise | Common Shares | 3,086 | $13.48 | $42K | |
| Gary Patou | Tax withholding / forfeiture | Common Shares | 1,046 | $39.80 | $42K | |
| Gary Patou | Open-market sale | Common Shares | 2,040 | $41.05 | $84K | |
| Gary Patou | Option exercise | Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
| Gary Patou | Option exercise | Stock Option (Right to Buy) | 3,086 | $0.00 | - |
Recent XENE Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| CHRISTOPHER KENNEY | Officer | 7,068 | $438K | View on EDGAR | |
| STEVEN GANNON | Director | 10,000 | $641K |
XENE insider trading FAQ
What is the latest insider trade for XENE?
Xenon Pharmaceuticals Inc. (XENE) had 5 insider filings in the last 90 days, with the most recent on 2026-10-01. The full record for XENE runs to 33 Form 4 filings, the earliest from 2024-11-22. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying XENE stock?
2 insider purchases of XENE were filed in the last 90 days, totaling $1.68M.
How many insiders are selling XENE stock?
3 insider sales of XENE were filed in the last 90 days, totaling $1.07M.
Where can I see XENE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects XENE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Thomas Patrick Kelly view on EDGAR
- - Ian Mortimer view on EDGAR
- - Dawn Svoronos view on EDGAR
- - Christopher John Kenney view on EDGAR
- - Steven Gannon view on EDGAR
- - Gary Patou view on EDGAR
- - Gillian Cannon view on EDGAR
- - Gary Patou view on EDGAR
- - Patrick Machado view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where XENE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow XENE with a 7-day demo
- XENE on your watchlist
- Every XENE Form 4 filing on record
- Up to 3 months of XENE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
